curacle co.,ltd. (KOSDAQ:365270)
South Korea · Delayed Price · Currency is KRW 13,450
+550 (4.26%)
At close: May 19, 2026
curacle co.,ltd. Revenue
In the year 2025, curacle co.,ltd. had annual revenue of 7.10M KRW, down -99.57%. curacle co.,ltd. had revenue of -10.00 in the quarter ending December 31, 2025.
Revenue
7.10M
Revenue Growth
-99.57%
P/S Ratio
39,329.32
Revenue / Employee
n/a
Employees
n/a
Market Cap
279.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.10M | -1.63B | -99.57% |
| Dec 31, 2024 | 1.63B | -8.66B | -84.14% |
| Dec 31, 2023 | 10.29B | 6.71B | 187.32% |
| Dec 31, 2022 | 3.58B | -2.67B | -42.72% |
| Dec 31, 2021 | 6.25B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 56.67B |
| Cell Biotech | 53.13B |
| CORESTEMCHEMON | 20.16B |
| TiumBio | 12.29B |
| QuadMedicine | 10.70B |
| Kangstem Biotech | 3.57B |
| Inventage Lab | 2.94B |
| Ensol Biosciences | 537.46M |